The CEO Magazine
A monthly magazine for business leaders and decision makers

Laurus Labs PAT Grows by 40%; Board Recommends a Dividend of 15%

35
Business Wire India

Laurus Labs Ltd. (Laurus), a leading R&D driven pharmaceutical company in India announces its Q4 & FY17 results.

 

FY17 Laurus reported:

 

  • Total Revenue rose 6.6% to Rs.18,919 mn as compared to Rs.17,746 mn
  • EBITDA higher by 19.3% at Rs.4,461 mn from Rs.3,740 mn
  • PAT increased 40.0% to Rs.2,026 mn from Rs.1,477 mn
  • EPS (Diluted) for the period stood at Rs.20 per share
  • The Board of Directors, at their meeting held on May 18, 2017, recommended a final dividend of Rs.1.50 per share, subject to the approval of shareholders.

Key Business Highlights

 

Overall

 

  • Prepayment of Loans resulted interest cost reduction apart from reduction in cost of funds
  • Capex investments in FY 17 Rs.3,155 million.
  • R & D opex investments Rs.1,050 million and 5.6% as percentage of sales in FY 17.
  • Unit IV expansion is in progress, the facility will add capacity to Generics API, Synthesis and Ingredients business.
  • Operations at Sriam (100% subsidiary of Laurus) Unit 2 started in FY 17.

Generic API

 

  • Laurus in partnership with Natco has launched Velpatasivir (Hep-C) product in India in May 2017.
  • As on Mar 17, the Company has filed 202 patent applications and 39 patents granted.
  • USFDA inspection scheduled in May 2017 for API facility.

Generic FDF

 

  • Filed 3 ANDAs and in addition completed 6 product validations in FY 17.
  • Capacity expansion of 5 billion tablets is in progress.
  • WHO inspection completed in March 2017.
  • FDF opex investments are Rs.982 million which includes Rs.335 million relating to the R& D in FY 17.
  • Company received EIR from USFDA for formulations unit 2.

Synthesis

 

  • Unit 5 (dedicated manufacturing facility for Aspen) has commenced validations in QE 31st Mar 17.

General

 

  • Received National Safety Award 2016 from Govt of India.
  • Received Best Management Award 2016 from Govt of AP.
  • Received Business Excellence Award 2017 from HMTV.
  • Dr. M. Venu Gopala Rao appointed as independent director and non-executive Chairman
  • Dr. Ravindranath Kancherla appointed as independent director
  • Mr. Krishna Chaitanya Chava son of Dr Satyanarayana Chava, CEO joined the Company as AVP Corporate Development in Apr 17.

BSE: 540222
NSE: LAURUSLABS
ISIN – NE947Q01010

 

 

 

 

Subscribe to our newsletter
Sign up here to get the latest news, updates and special offers delivered directly to your inbox.
You can unsubscribe at any time
You might also like
Comments